Printer Friendly

UNIGENE ANNOUNCES APPROVAL OF KEY EUROPEAN PATENT

 FAIRFIELD, N.J., March 22 /PRNewswire/ -- Unigene Laboratories, Inc. (NASDAQ: UGNE), announced today that the European Patent Office has notified the company of its intention to grant its key patent, describing the technology for efficiently producing a large class of peptide hormones including calcitonin. The process patent, which will formally issue in due course, is the broadest of the company's three related patent applications in Europe and the first one to receive approval. While patents based on the technology have issued in other countries including the United States, the approval is significant because Europe represents the world's largest and fastest growing market for calcitonin. Current European sales of calcitonin account for approximately 75 percent of the nearly $1 billion worldwide total.
 The company currently uses the process to produce highly-purified calcitonin to support its development of an oral calcitonin formulation, to compile data required for the registration of the drug for osteoporosis and other indications, and to sell internationally to the research community. The process can also be used to produce many other important hormones which are being evaluated as treatments for hypertension, diabetes, wounds, ulcers and inflammation.
 Unigene Laboratories is a biotechnology company which develops technology and products with applications in the health care field.
 -0- 3/22/93
 /CONTACT: Dr. Ronald S. Levy, vice president of Unigene, 201-882-0860/
 (UGNE)


CO: Unigene Laboratories, Inc. ST: New Jersey IN: MTC SU:

TS-GK -- NY027 -- 8108 03/22/93 09:49 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 22, 1993
Words:240
Previous Article:URI GELLER WINS JAPANESE LEGAL ACTION
Next Article:FEMALE CONDOM IS AWKWARD, COMICAL, CALIFORNIA SCIENTISTS TELL SELF MAGAZINE
Topics:


Related Articles
Unigene Files For Registration of Its Injectable Osteoporosis Product in Europe
Unigene Awarded New U.S. Patent on Manufacturing Process for Osteoporosis Product
Unigene Receives First Product Approval; Injectable Calcitonin Product Approved in European Union.
Unigene Awarded U.S. Patent for Oral Delivery of Osteoporosis Product.
Unigene awarded United States patent for oral delivery of osteoporosis product.
Unigene Receives $2.5 Million Milestone Payment From Warner-Lambert.
Unigene Reports Progress in Key Programs and Products.
Unigene's Injectable Calcitonin Product Receives Its First Approval for Osteoporosis.
Unigene's Joint Venture Launches Calcitonin Product in China.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters